{"id":620,"date":"2020-10-31T07:21:22","date_gmt":"2020-10-31T07:21:22","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=620"},"modified":"2020-10-31T07:21:22","modified_gmt":"2020-10-31T07:21:22","slug":"29-oct-2020-anakinra-associated-with-decrease-of-the-risk-for-severe-respiratory-failure","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/29-oct-2020-anakinra-associated-with-decrease-of-the-risk-for-severe-respiratory-failure\/","title":{"rendered":"(29 Oct 2020) Anakinra- associated with decrease of the risk for severe respiratory failure"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Anakinra To Prevent Respiratory Failure In COVID-19<\/p>\n<p>https:\/\/www.medrxiv.org\/content\/10.1101\/2020.10.28.20217455v1<\/p>\n<p class=\"\">In this open-label prospective trial (NCT04357366), 130 patients admitted with SARS-CoV-2 pneumonia SARS-CoV-2 and suPAR levels \u22656 \u03bcg\/l were assigned to subcutaneous anakinra 100mg once daily for 10 days. The primary outcome was the incidence of SRF at day 14. Secondary outcomes were 30-day mortality, changes in sequential organ failure assessment (SOFA) score, of cytokine-stimulation pattern and of circulating inflammatory mediators. The incidence of SRF was 22.3% (95% CI, 16.0-30.2%) among anakinra-treated patients and 59.2% (95% CI, 50.6-67.3%; P: 4.6 x 10-8) among SOC comparators (hazard ratio, 0.30; 95%CI, 0.20-0.46). 30-day mortality was 11.5% (95% CI, 7.1-18.2%) and 22.3% (95% CI, 16.0-30.2%) respectively (hazard ratio 0.49; 95% CI 0.25-0.97%; P: 0.041). Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10\/IL-6 ratio on day 7 was inversely associated with the change in SOFA score. Duration of stay at the intensive care unit and at hospital was shortened compared to the SOC group; the cost of hospitalization was decreased. Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- \/anti-inflammatory balance.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Anakinra To Prevent Respiratory Failure In COVID-19 https:\/\/www.medrxiv.org\/content\/10.1101\/2020.10.28.20217455v1 In this open-label prospective trial (NCT04357366), 130 patients admitted with SARS-CoV-2 pneumonia SARS-CoV-2 and suPAR levels \u22656 \u03bcg\/l were assigned to subcutaneous anakinra 100mg once daily for 10 days. The primary outcome&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/29-oct-2020-anakinra-associated-with-decrease-of-the-risk-for-severe-respiratory-failure\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(29 Oct 2020) Anakinra- associated with decrease of the risk for severe respiratory failure&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[56,4],"tags":[57],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/620"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=620"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/620\/revisions"}],"predecessor-version":[{"id":621,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/620\/revisions\/621"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=620"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=620"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}